AstraZeneca Q210 Results Highlight The Company's Exposure To Government Austerity Measures

BMI believes AstraZeneca's Q210 results reinforce our view that emerging markets will drive industry growth. The company delivered a strong performance in H110, posting a 7% increase in net sales compared with H109 to reach US$16.75bn. However, on comparing AstraZeneca's financial performance between Q109 and Q110 it is evident that the company has suffered at the hands of cost-containment measures implemented by governments in developed states - particularly by governments across Europe - over the past six

To read the full article, please choose one of the following options: